Evidence Hub

The Role of Phosphodiesterase-5 Enzyme Inhibitors and Prostacyclin Analogs in Reactive Pulmonary Vasculopathy in Systolic Heart Failure: A Narrative Review

Sekharamahanti HE, Patel DV, Prajapati M, Sirekulam V, Shah P, Peracha HT, Patel S, Makineni KS et al.

Cureus, 2025

Abstract

Reactive pulmonary vasculopathy, the precapillary component of pulmonary hypertension due to left heart disease, is characterized by mean pulmonary arterial pressure >25 mmHg, pulmonary capillary wedge pressure >15 mmHg, transpulmonary gradient ≥12 mmHg, and pulmonary vascular resistance ≥3 Wood units. This condition complicates systolic heart failure and is associated with adverse outcomes. This narrative review evaluates the role of phosphodiesterase-5 (PDE-5) inhibitors and prostacyclin analogs in its management. A comprehensive literature search of PubMed, Cochrane Library, and Embase from January 2000 to September 2024, supplemented by reference screening, identified randomized controlled trials, observational studies, and case series investigating these therapies in systolic heart failure with pulmonary hypertension. Evidence synthesis considered both hemodynamic outcomes, such as pulmonary pressures, vascular resistance, and right ventricular function, as well as clinical endpoints, including exercise capacity, quality of life, and survival. PDE-5 inhibitors, particularly sildenafil, demonstrated improvements in pulmonary hemodynamics, endothelial function, and exercise tolerance, while prostacyclin analogs such as epoprostenol, iloprost, and treprostinil provided potent vasodilatory and antiproliferative effects with benefits in advanced disease and right ventricular protection. Combination therapy has shown potential synergistic effects, although data remain…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free